Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Operations (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Cash from Operations for 11 consecutive years, with 17712000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 152.96% to 17712000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 73941000.0 through Dec 2025, down 212.33% year-over-year, with the annual reading at 73941000.0 for FY2025, 212.33% down from the prior year.
  • Cash from Operations for Q4 2025 was 17712000.0 at Cartesian Therapeutics, down from 15600000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 13691000.0 in Q3 2024, with the low at 31460000.0 in Q4 2021.
  • Average Cash from Operations over 5 years is 12039450.0, with a median of 11998500.0 recorded in 2021.
  • The sharpest move saw Cash from Operations crashed 333.93% in 2021, then surged 248.57% in 2024.
  • Over 5 years, Cash from Operations stood at 31460000.0 in 2021, then skyrocketed by 62.34% to 11849000.0 in 2022, then crashed by 96.52% to 23286000.0 in 2023, then skyrocketed by 69.93% to 7002000.0 in 2024, then plummeted by 152.96% to 17712000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 17712000.0, 15600000.0, and 17521000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.